MarketCap
Facebook
X
Telegram
Checkpoint Therapeutics Income Statement 2024-2011 | CKPT
Brief overview of income trends at Checkpoint Therapeutics
The figures are compared over a five-year interval. Revenue reported by Checkpoint Therapeutics was 1.7 million dollars at the beginning of the period and 41 thousand dollars at the end. The cumulative result was −97.6%, corresponding to roughly −52.6% per year. Sales followed a declining trajectory over the five years.
EBITDA changed from −24.9 million dollars to −56.2 million dollars (−126.1%). The operating result developed less favorably than sales. At the operating-margin level, the figure shifted from −1454.9% to −137009.8%. Cost pressure reduced operating profitability.
Net income moved from −24.7 million dollars at the start to −56.2 million dollars at the end. The period ended with a larger loss than it began with.
Financial takeaway
The results contain several connected negative signals. The weaker side of the profile includes limited revenue growth, limited operating profitability and a declining EBITDA margin. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Checkpoint Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
160 M | 36.4 M | 32.8 M | 13.6 M | 181 M | 63.9 M | 108 M | 90.5 M | 237 M | - | - | - | - | - |
Shares |
39.7 M | 18.7 M | 8.84 M | 7.6 M | 55.8 M | 35.3 M | 28.6 M | 22.6 M | 21.5 M | - | - | - | - | - |
Historical Prices |
4.04 | 1.94 | 3.71 | 1.79 | 3.21 | 1.75 | 2.79 | 4.5 | 15 | - | - | - | - | - |
Net Income |
-56.2 M | -51.8 M | -62.6 M | -56.7 M | -23.1 M | -24.7 M | -36.4 M | -22.7 M | -22.5 M | -13.9 M | - | - | - | - |
Revenue |
41 K | 103 K | 192 K | 268 K | 1.07 M | 1.71 M | 3.51 M | 1.72 M | 2.57 M | 590 K | - | - | - | - |
Gross Profit |
- | - | - | - | 1.07 | - | - | - | - | - | - | - | - | - |
Operating Income |
-56.2 M | -52.1 M | -58.3 M | -56.7 M | -23.2 M | -24.8 M | -36.7 M | -22.8 M | -22.2 M | -13.2 M | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | - | - | 344 K | 235 K | - | - | - | - |
EBITDA |
-56.2 M | -52.1 M | -58.3 M | -56.7 M | -23.2 M | -24.8 M | -36.7 M | -22.7 M | -22.1 M | -13.2 M | - | - | - | - |
Operating Expenses |
56.2 M | 52.3 M | 58.5 M | 57 M | 24.3 M | 26.6 M | 40.2 M | 24.5 M | 24.7 M | 13.8 M | - | - | - | - |
General and Administrative Expenses |
20.1 M | 8.68 M | 8.7 M | 8.54 M | 7.92 M | 7.23 M | 6.59 M | 5.42 M | 4.47 M | 2.49 M | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement Checkpoint Therapeutics
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
59.8 M | 53.6 M | 43.2 M | 36.5 M | 32.9 M | 27 M | 20 M | 15.7 M | 11.7 M | 9.59 M | 8.86 M | 8.75 M | 8.5 M | 77.6 M | 78.5 M | 75.5 M | 70.3 M | 62.4 M | 56.4 M | 51.8 M | 50.9 M | 47 M | 34.6 M | 32.7 M | 32.2 M | 27.1 M | 29.2 M | 29 M | 24.8 M | 18.5 M | 22.8 M | 22.7 M | 22.1 M | 17.4 M | 21.8 M | 21.7 M | 20.8 M | 16 M | 8.53 M | - | - | 8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-11.2 M | - | -9.72 M | -6.67 M | -10.9 M | - | -5.72 M | -16.5 M | -10.5 M | - | -10.6 M | -14.1 M | -16.8 M | - | -11.3 M | -9.14 M | -6.5 M | - | -4.93 M | -4.64 M | -3.28 M | - | -5.21 M | -4.79 M | -5.89 M | -11.6 M | -9.34 M | -6.64 M | -8.76 M | -5.92 M | -5.93 M | -6.45 M | -4.38 M | -8.32 M | -5.13 M | -5.4 M | -3.6 M | -8.05 M | -3.75 M | -475 K | -1.62 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
- | - | - | 41 K | - | - | 31 K | 31 K | 35 K | - | 48 K | 18 K | 52 K | - | 29 K | 155 K | 68 K | - | 28 K | 42 K | 972 K | - | 280 K | 1.05 M | 352 K | 3.03 M | 5 K | 127 K | 343 K | 332 K | 349 K | 351 K | 693 K | 498 K | 546 K | 1.25 M | 277 K | 65 K | 25 K | - | 500 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-11.1 M | - | -9.72 M | -6.67 M | -10.9 M | - | -7.7 M | -16.2 M | -18.1 M | - | -10.7 M | -14.2 M | -16.9 M | - | -11.3 M | -9.16 M | -6.52 M | - | -4.94 M | -4.67 M | -3.34 M | - | -5.23 M | -4.83 M | -5.93 M | - | -9.39 M | -6.68 M | -8.78 M | - | -5.95 M | -6.47 M | -4.41 M | - | -5.14 M | -5.42 M | -3.27 M | - | -3.68 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 344 K | - | 70 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-11.1 M | - | -9.72 M | -6.67 M | -10.9 M | - | -7.7 M | -16.2 M | -18.1 M | - | -10.7 M | -14.2 M | -16.9 M | - | -11.3 M | -9.16 M | -6.52 M | - | -4.94 M | -4.67 M | -3.34 M | - | -5.23 M | -4.83 M | -5.93 M | - | -9.39 M | -6.68 M | -8.78 M | - | -5.95 M | -6.47 M | -4.41 M | - | -5.14 M | -5.42 M | -3.27 M | - | -3.68 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
11.1 M | - | 9.72 M | 6.71 M | 10.9 M | - | 7.73 M | 16.2 M | 18.1 M | - | 10.7 M | 14.2 M | 16.9 M | - | 11.3 M | 9.31 M | 6.59 M | - | 4.97 M | 4.72 M | 4.31 M | - | 5.51 M | 5.88 M | 6.28 M | 14.9 M | 9.39 M | 6.8 M | 9.13 M | 6.27 M | 6.3 M | 6.82 M | 5.11 M | 8.83 M | 5.68 M | 6.67 M | 3.55 M | 7.52 M | 3.7 M | 475 K | 2.12 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
7.36 M | - | 3.36 M | 2.23 M | 2.45 M | - | 2.24 M | 2.28 M | 2.29 M | - | 1.85 M | 2.13 M | 2.24 M | - | 1.92 M | 2.11 M | 2.37 M | - | 2.43 M | 1.69 M | 1.68 M | - | 1.62 M | 1.76 M | 1.7 M | - | 1.54 M | 1.35 M | 2.19 M | - | 1.34 M | 1.32 M | 1.4 M | - | 972 K | 1.22 M | 1.18 M | - | 219 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Checkpoint Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
